|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/23/22 MediXall Group, Inc. 10-Q 6/30/22 47:2.7M Edgar Filing LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 560K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 17K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 17K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 15K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 14K
11: R1 Cover HTML 64K
12: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 103K
13: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 37K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Operations HTML 88K
(Unaudited)
15: R5 Consolidated Statements of Changes in HTML 68K
Stockholders' Equity (Deficit) (Unaudited)
16: R6 Consolidated Statements of Changes in HTML 17K
Stockholders' Equity (Deficit) (Unaudited)
(Parenthetical)
17: R7 Condensed Consolidated Statements of Cash Flows HTML 84K
(Unaudited)
18: R8 Organization and Nature of Operation HTML 20K
19: R9 Asset Acquisition HTML 19K
20: R10 Going Concern HTML 21K
21: R11 Summary of Significant Accounting Policies HTML 71K
22: R12 Right-to-use Intellectual Property HTML 30K
23: R13 Preferred Stock HTML 25K
24: R14 Related Party Transactions HTML 35K
25: R15 Senior Convertible Debentures and Warrants HTML 31K
26: R16 Summary of Significant Accounting Policies HTML 106K
(Policies)
27: R17 Summary of Significant Accounting Policies HTML 49K
(Tables)
28: R18 Right-to-use Intellectual Property (Tables) HTML 30K
29: R19 Related Party Transactions (Tables) HTML 26K
30: R20 Senior Convertible Debentures and Warrants HTML 25K
(Tables)
31: R21 Asset Acquisition (Details Narrative) HTML 22K
32: R22 Going Concern (Details Narrative) HTML 23K
33: R23 Summary of Significant Accounting Policies HTML 28K
(Schedule of Basic and Diluted EPS) (Details)
34: R24 Summary of Significant Accounting Policies HTML 22K
(Schedule of potentially dilutive securities)
(Details)
35: R25 Summary of Significant Accounting Policies HTML 20K
(Details Narrative)
36: R26 Right-to-use Intellectual Property (Schedule of HTML 22K
Right-to-use Intellectual Property) (Details)
37: R27 Right-to-use Intellectual Property (Schedule of HTML 30K
amortization expense for right-to-use intellectual
property) (Details)
38: R28 Preferred Stock (Details Narrative) HTML 37K
39: R29 Related Party Transactions (Details) HTML 32K
40: R30 Related Party Transactions (Details Narrative) HTML 32K
41: R31 Senior Convertible Debentures and Warrants HTML 31K
(Details)
42: R32 Senior Convertible Debentures and Warrants HTML 42K
(Details Narrative)
45: XML IDEA XML File -- Filing Summary XML 78K
43: XML XBRL Instance -- mdxl_10q_htm XML 587K
44: EXCEL IDEA Workbook of Financial Reports XLSX 71K
7: EX-101.CAL XBRL Calculations -- mdxl-20220630_cal XML 106K
8: EX-101.DEF XBRL Definitions -- mdxl-20220630_def XML 225K
9: EX-101.LAB XBRL Labels -- mdxl-20220630_lab XML 491K
10: EX-101.PRE XBRL Presentations -- mdxl-20220630_pre XML 396K
6: EX-101.SCH XBRL Schema -- mdxl-20220630 XSD 85K
46: JSON XBRL Instance as JSON Data -- MetaLinks 205± 289K
47: ZIP XBRL Zipped Folder -- 0001553350-22-000715-xbrl Zip 129K
Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of MediXall Group, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Noel Guillama-Alvarez, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: August 23, 2022 | /s/ Noel Guillama-Alvarez |
| Noel Guillama-Alvarez | |
| Interim Chief Executive Officer | |
| (principal executive officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/23/22 | |||
| For Period end: | 6/30/22 | NT 10-Q | ||
| List all Filings | ||||